Merck and Moderna said intismeran autogene, an mRNA cancer vaccine that prompts an immune response to proteins expressed by a patient’s tumors, met the main goal of a pivotal test in melanoma. It’s the most advanced trial in a 50/50 partnership evaluating the personalized cancer treatment in a wide range of tumor types.
The post Merck, Moderna Personalized mRNA Cancer Therapy Achieves a First for Melanoma appeared first on MedCity News.
